Navigation Links
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
Date:12/12/2008

EAST HANOVER, N.J., Dec. 12 /PRNewswire/ -- New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab)* in women with HER2-positive metastatic breast cancer. These results support the initiation of a Phase III clinical trial program to fully explore the potential of RAD001 (proposed brand name Afinitor(R)) in breast cancer.

Two Phase I studies were presented today during the CTRC-AACR San Antonio Breast Cancer Symposium. Initial results from both studies were released earlier this year at the American Society of Clinical Oncology (ASCO) annual meeting.

Updated results from the first Phase I trial show that the combination of RAD001 with Herceptin and weekly Taxol(R) (paclitaxel)** halted tumor growth in 77% of patients with HER2-positive metastatic breast cancer with documented resistance to Herceptin. In addition, the data demonstrated the first complete response in the trial.

In addition, updated data from the second Phase I study show promising anticancer activity for RAD001 in combination with Herceptin and Navelbine(R) (vinorelbine)*** in heavily pretreated Herceptin-resistant patients with HER2-positive metastatic breast cancer. In the study, RAD001 in combination with Herceptin and Navelbine halted tumor growth in 62% of patients.

"Data presented at this meeting affirm the potential of RAD001 to reverse Herceptin resistance and restore patient response to treatment," said Ruth O'Regan, MD, Emory University School of Medicine, Atlanta, GA. "These findings are important for patients with HER2-positive metastatic breast cancer who develop resistance to Herceptin."

Preclinical data have shown that RAD001, an inhibitor of mTOR, acts on the pathway that mediates Herceptin resistance and has the potential to help restore response in these patients. RAD001 works through direct antitumor activit
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
2. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
3. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
4. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
5. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
6. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
7. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
10. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
11. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... PARIS , Sept. 30, 2014 ... and NYSE: SNY) today announced that a Phase 2a ... IL-4 and IL-13 signaling, met all primary and secondary ... polyps (CSwNP) who did not respond to intranasal corticosteroids. ... dupilumab for use in the treatment of another allergic ...
(Date:9/29/2014)... PHILADELPHIA , Sept. 29, 2014  Repeated exposure ... life is associated with early childhood obesity, say researchers ... in a retrospective study based on data from ... The researchers found that children with ... infancy were particularly more likely to be at risk ...
(Date:9/29/2014)... DIEGO , 29 septembre 2014 ... (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ont ... fusion définitif en vertu duquel Daiichi Sankyo fera ... circulation d,Ambit Biosciences à 15 dollars par action ... d,achat qui sera suivie d,une fusion avec une ...
Breaking Medicine Technology:Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... AUSTIN, Texas, May 24, 2011 A paper published ... demonstrated that adding OVA1 to a physician,s preoperative ... ovarian cancers than a physician,s preoperative assessment alone. The ... the journal, which is the official publication of the ...
... Holdings, Inc. (OTCQB: ABHI), a leader in the development of ... has signed a new line of credit with East West ... to expire July 2011. The new line of credit expands ... the previous revolving line and extends the line by one ...
Cached Medicine Technology:OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 2OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 3OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 4AmbiCom Renews and Expands Line of Credit With East West Bank 2AmbiCom Renews and Expands Line of Credit With East West Bank 3
(Date:9/30/2014)... 30, 2014 Influenza is a significant ... can improve the efficacy of therapy, minimize overuse of ... disease in healthcare settings. Diagnostic tests available today vary ... The decision your laboratory makes in selecting the correct ... providers, is key to effective use of influenza diagnostics. ...
(Date:9/30/2014)... 3M has added four new thin VHB ... 3M 5906 , 3M 5907 , 3M ... which help create the strongest bond possible to a wide ... bonding to difficult surfaces such as paints, low surface energy ... and 5905 are designed specifically for electronic device engineers and ...
(Date:9/30/2014)... Seniors Guide will take part in running ... in Raleigh, to support Alzheimer’s North Carolina (AlzNC) in ... , Associate Publisher of Seniors Guide Magazine, Shannon Tippette, ... for the Raleigh-Durham-Chapel Hill areas of North Carolina for ... helping their team, “Eye of the Tiger”, reach their ...
(Date:9/30/2014)... 30, 2014 American Medical ID and ... agreement to raise awareness about Alzheimer’s disease and related ... people with these brain disorders. , American Medical ID ... AFA to the foundation to support its efforts to ... The ID bracelets and necklaces can be purchased via ...
(Date:9/30/2014)... Charlestown, RI (PRWEB) September 30, 2014 Dogs ... owner. Oftentimes, this involves spending time in the car travelling ... their canines have free run of the vehicle; however, this ... the owner as well. Royal Flush Havanese shares ... should always be routine practice. , There are many ways ...
Breaking Medicine News(10 mins):Health News:Alere Webinar Spotlights Optimal Flu Diagnostics to Keep Your Lab Ahead of the Curve 2Health News:Alere Webinar Spotlights Optimal Flu Diagnostics to Keep Your Lab Ahead of the Curve 3Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 2Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... in circuits that regulate serotonin in certain parts of the ... cocaine-seeking, based on mouse studies published online this week in ... "The impetus for this research was our interest in ... in ways that lead to mood changes, depression, anxiety, and ...
... cuts conception rate, study found , THURSDAY, Oct. 29 ... minutes after being artificially inseminated greatly boost their odds ... treated for subfertility with IUI [intrauterine insemination] to remain ... chance at conceiving," said Inge Custers, lead author of ...
... ... Me Not Flower Club ("FMN-FC") today announced the launch of its online floral gift ... as well as other diseases associated with aging. , ... Camarillo, California (PRWEB) October 30, 2009 -- In ...
... expert offers tips for those thrown off schedule by Daylight ... That extra hour of sleep you,ll get in most parts ... the beginning of Daylight Saving Time could spell trouble for ... Atul Malhotra, medical director of the sleep disorders research program ...
... expectant moms led to bigger, healthier infants, studies show ... women head the list of people who should get ... new studies highlight the benefits of vaccination for moms-to-be ... births and reduced rates of hospitalization top the findings, ...
... , VIRGINIA BEACH, Va., Oct. 30, 2009 AMERIGROUP Corporation (NYSE: ... quarter of 2009 was $22.5 million, or $0.43 per diluted share, ... quarter of 2008. Third quarter earnings are in line with ... October 26, 2009, and reflect elevated medical costs associated ...
Cached Medicine News:Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 2Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 3Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 2Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: